Adam Marcus, Agustin Armendariz, American Association of Cancer Research, Anonymous Commenter, Carlo Croce, Character Assassination, Clare Francis, Corruption, Data Fabrication, Data Falsification, Defamation, Defamation lawsuit, Fernando Pessoa (Retraction Watch), First Amendment to US Constitution, Fraud, Ivan Oransky, James Glanz, New York Times, NIH funding, Office of Research Integrity, Ohio Southern District Court, Ohio State University, Paul S. Thaler, Post Publication Peer Review Scam, PubPeer, Reporting Retractions, Reputation Damage, Retraction Watch, Scientific corruption, Scientific Integrity, Scientific Misconduct, Scientific publication

Carlo Croce sued The New York Times; he should not spare Retraction Watch

Carlo M. Croce is a towering figure in cancer genetics. His discovery of the molecular mechanisms in leukemia and other malignancies places him in the league of pioneers in the field like Janet Rowley. Croce’s peers have recognized his contributions, elected him to the US National Academy of Science in 1996 and showered him with prizes. Notwithstanding his success, concerns about the integrity of Croce’s work are surfacing and certain people seem to be now investing in his downfall. A while back, MIT Nobel laureate Philip Sharp praised him but detected some sloppiness in his work, while UC Berkeley Nobel laureate Randy Schekman claimed that as editor he became aware of certain allegations concerning Croce’s research published in the Proceedings of the National Academy of Sciences.

 

InBev+Baillet+Latour+Awards+de+la+Sante+2013+rT6H1wjTGQHl

The 2013 prize of the Artois-Baillet Latour Foundation given by HRH The Queen of Belgium to Carlo M. Croce.

Croce’s fall from grace happened when he was defamed in an article published in the New York Times on March 8 of this year. The authors of the article, James Glanz and Agustin Armendariz, tell us that Croce had been dodging misconduct allegations for decades, and that a major cover-up was put up by Ohio State University (OSU), Croce’s home institution, because he was bringing millions of dollars in grant overhead each year. Glanz and Armendariz tell us that Croce, the discoverer of cancer mechanisms that saved the lives of thousands, had been cheating all along but “was too big to make findings of misconduct on”.

The entire scientific community was in a state of shock at what seemed to be a flagrant act of defamation. In America, as in most countries under the rule of law, Croce should be presumed innocent unless proven otherwise, and his innocence should be protected at all cost, as it seemed to have been the case with OSU’s internal investigation. It came as a shock to everybody that these unresolved or closed investigations would be exposed in a major venue like the NYT, destroying in one stroke Croce’s reputation earned through decades of hard work. Yet, most of the scientific community dismissed these unproven allegations: on March 29, a few days after the defamatory article appeared in the NYT, the American Association of Cancer Research made Carlo Croce the recipient of the Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research.  Not surprisingly, this recognition emboldened Croce. Carlo Croce sued the NYT in Court for defamation a few weeks later. The particulars of the lawsuit are as follows:

Croce v. New York Times Company et al (case filed May 10, 2017)

Ohio Southern District Court
Judge: James L Graham
Referred: Terence P Kemp
Case #: 2:17-cv-00402
Nature of Suit 320 Torts – Personal Injury – Assault, Libel, & Slander
Cause 28:1332 Diversity-Libel,Assault,Slander

The lingering question is who instigated the NYT article and emboldened Glanz and Armindariz? Why would Glanz and Armendariz risk everything to go after a towering figure in cancer research, whose discoveries saved thousands of lives, with nothing more that conjectures and unproven allegations over sloppiness in reporting or conducting scientific research? Glanz and Armendariz were fueled, emboldened, enabled and inspired by a blog name Retraction Watch, the true instigator of Carlo Croce’s downfall and, specifically, of the NYT defamation piece.

Retraction Watch purportedly reports on scientific misconduct. Yet Retraction Watch is engaged in the most corrupt and less transparent scheme imaginable. To generate enough activity, the Retraction Watch founders created two anonymous characters, giving them writers’ names: Clare Francis and Fernando Pessoa. Clare Francis operates in secrecy, while Fernando Pessoa operates in the open. Unchecked allegations, including all kinds of inanities, personal attacks, etc. are first received by Ivan Oransky and Adam Marcus, the two medicine/science dropouts who founded Retraction Watch. Then, Oransky and his pal make sure these allegations turn into substantial news that can be reported by Retraction Watch. Soon after the unchecked allegations emanating from any source (literally any) land on Oransky’s desk, they get funneled by Clare Francis in the most brazen threatening terms imaginable to journals, institutions and individuals, that get harassed and coerced into taking immediate action. According to the journal editors, over 90% of the allegations by Clare Francis are simply gibberish. Once some scathing reaction, for example a journal retraction, is elicited by Clare Francis and gets out in the open, Retraction Watch immediately reports it, broadcasting the scathing news in the harshest terms possible. Retraction Watch can do this extremely swiftly, usually the very same day the reaction becomes public, obviously because Clare Francis is the secret arm of Retraction Watch: they generate the same news they broadcast. Immediately after Retraction Watch publishes their piece, Fernando Pessoa comments profusely on it adding other instances of perceived misconduct allegedly committed by the person under attack. Obviously, Fernando Pessoa can also act so swiftly and thoroughly on each case simply because it is also part of Retraction Watch. To summarize, first the secret arm Clare Francis elicits reactions by journals, institutions and individuals that are brazenly approached with misconduct accusations, then Retraction Watch openly scorns and humiliates the accused person in the harshest terms possible, and finally Fernando Pessoa adds as much salt to the injury as possible. That is how the coward defamation scheme works, as anyone with a moderate ability to think can figure out by reading Retraction Watch.

Let us now focus on Retraction Watch chasing and pillorying of Carlo Croce and on its inspirational enabling role in the NYT investigation. One of the most striking details of the NYT article is its identification by Glanz and Armendariz of Clare Francis, the secret arm of Retraction Watch, as the agent who brashly brought up thirty or more misconduct allegations against Carlo Croce to the attention of OSU authorities. It should be noted that Croce had been profusely attacked and defamed by Retraction Watch prior to the appearance of the NYT article, on May 5, 2014, on April 6, 2015, on October 10, 2016 and, especially, on January 24, 2017, when Fernando Pessoa, the second arm of Retraction Watch, added 15 (fifteen) scathing comments against Carlo Croce on the very same day! In this way, all of Clare Francis accusations presented to OSU were fully covered also by Retraction Watch. On March 8, 2017, within a few hours after the NYT article came out, Retraction Watch published its own fiercely scathing article against Carlo Croce, covering the NYT defamation in gory detail and even amplifying the damage, and this time Fernando Pessoa added 13 (thirteen) comments describing more instances of misconduct allegedly committed by Carlo Croce. On March 15, another article damaging Carlo Croce came out at Retraction Watch, but the apotheosis came on March 30, 2017, a day after the AACR prize to Carlo Croce was announced. Oransky and his pal were truly incensed. On March 30, 2017 in an article entitled “Cancer org bestows award on scientist under investigation“, Retraction Watch expressed its outrage that Carlo Croce, a person seriously suspected of misconduct, would be given a prize by a “Cancer org” (Retraction Watch was referring to the American Association of Cancer Research). Fernando Pessoa swiftly added three scathing comments that day. Retraction Watch kept of defaming Croce on April 3, 2017 (Fernando Pessoa added 9 nasty comments this time), June 9, August 29, and September 8, 2017, with Fernando Pessoa adding scathing comments each time.

Carlo Croce sued the NYT for defamation. He should not spare Retraction Watch, the instigator and enabler of the NYT article. Oransky and his pal Marcus should be served in court for the great disservice they are doing to science and to the people whose lives are saved every day thanks to Croce’s discoveries.

Advertisements
Standard
Cancer Research, Carlo Croce, Character Assassination, Civil Death, Clare Francis, Data Fabrication, Data Falsification, Defamation, Defamation lawsuit, First Amendment to US Constitution, Fraud, Ivan Oransky, National Institutes of Health, New York Times, NIH, NIH funding, Office of Research Integrity, Ohio State University, Paul S. Thaler, protected free speech, Research misconduct, Retraction Watch, Scientific corruption, Scientific publication

Stellar cancer researcher Carlo Croce falls from grace: hypocrisy in science

Last week The New York Times published a front-page story entitled “Years of Ethics Charges but Star Cancer Researcher Gets a Pass“.  The article grossly disparages Prof. Carlo Croce, a towering figure in cancer biology and genetics, and his home institution, The Ohio State University. It describes in some detail multiple accusations of misconduct and malfeasance that have been targeting Croce for years.

bio_croce

Dr. Carlo M. Croce, Ohio State University

We are told that Croce has been dodging grave allegations that he falsified data in research supported by more than $86 million in federal grants that have been awarded to him. The investigative task of the Times reporters was greatly facilitated by the fact that the records at Ohio’s courthouses and its university system are completely open to the public. And Ohio State University, which claims it had spent more money supporting Dr. Croce’s research than it had received in grants, was apparently totally responsive to requests for records.

The big problem with all this is that to this day there is no hard evidence of misconduct implicating Croce. Ohio State had repeatedly investigated Croce and cleared him of wrongdoing every single time. How disinterested these investigations were is of course a matter of debate.

Since Dr. Carlo Croce has not been proven guilty of misconduct by the preponderance of evidence, the public does not have the right to know about these investigations and he must be presumed innocent. The integrity of Croce’s career should have been protected. The New York Times article is actionable in Court.

The most astonishing aspect of the story is that neither government agencies nor Ohio State believed Croce would be seriously investigated for misconduct, since he is one of Ohio State biggest rainmakers. This bespeaks of a system corrupt to the marrow and draws a lesson that epitomizes the level of hypocrisy that plagues the science establishment.

Of course we wonder who sent James Glanz, the Times reporter, the documents that appeared in Mr. Glanz’s email inbox, in what his collaborator Agustin Armendariz calls three big dumps. This is anyone’s guess. The Times story mentions Clare Francis, the pseudonym for an agent for the blog Retraction Watch, whose brash nauseating style is reminiscent of Ivan Oransky’s writing…

In any case, that would be discovered in Court if and when Dr. Carlo M. Croce decides to take legal action.

Standard
美国国立卫生研究院, Howard Hughes Medical Institute, John Ioannidis, National Institutes of Health, NIH, NIH funding, Peer Review, Principal Investigator, Research grant, Study Section

Peer Review: Is NIH Rewarding Talent?

In a striking analysis published in Nature, Stanford University researcher John Ioannidis, the expert on metadata investigation at the Stanford Prevention Research Center, has seriously questioned the way the National Institutes of Health fund research proposals. He and his colleague Joshua Nicholson have argued in what seems like a rousing condemnation of the status quo that peer-review, the process by which study sections review and rank research applications, is totally broken.  The researchers argued that peer review at NIH (简称) encourages “conformity, if not mediocrity”, favoring proposals submitted by people who know how to network and play the petty games of academic sociology, rather than those by people who have original and potentially influential ideas.

These conclusions rest heavily on the observation that only 40 percent of scientists with highly cited papers (say, those with more than 1000 citations) are principal investigators on NIH grants. That is, those scientists whose peers value their work most highly are often not receiving NIH support for that work.

Of course, the analysis may be imperfect. Here is my critique for one: Using high citation level as a proxy for originality is probably not entirely correct (but then what is a good proxy for originality?). It is also possible that a good percentage of these investigators have not even applied for NIH funding in the first place. And, finally, they may have other sources of support for their research, most likely, the Howard Hughes Medical Institute (should we then conclude that HHMI funds more original research than NIH?).

It is perhaps true that the peer review system is broken. The majority of the authors of the most influential papers in medicine and the life sciences seem not to have NIH funding according to Ioannidis and Nicholson, and their funding rate is possibly less than average. Perhaps the most disturbing observation, the one that truly needs the closest scrutiny, is that study section members are almost always funded while their citation impact is typically low or average: they are not the high-impact innovators.

This leaves us with a sad reflection. Probably a truly innovative idea cannot be appreciated by the peers, while if peers can readily grasp it (to the level they are willing to fund it), it is probably not innovative.

NIH is seemingly aware of this problem and has earnestly tried to address these concerns introducing specific award categories such as the Pioneer and New Innovator Awards. Perhaps Ioannidis and Nicholson may be willing to evaluate the efficacy of these categories in capturing true talent.

Standard